ReviewFrontiers in oncology2026
Advances in proton therapy technology and global clinical applications.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Proton therapy, by leveraging its unique physical characteristic of the Bragg peak, enables high-precision dose delivery to the tumor target while effectively protecting surrounding normal tissues, and has become an important representative of advanced radiotherapy. This review aims to systematically summarize key technological breakthroughs in recent years that have driven the progress of proton therapy, including compact superconducting accelerators, pencil beam scanning (PBS), image-guided proton therapy (IGPT), and the transformative ultra-high dose rate FLASH radiotherapy, while highlighting the role of artificial intelligence (AI) in advancing proton therapy toward real-time adaptive precision radiotherapy. The article also explores the global distribution and development status of proton centers, with a specific analysis of China's notable advancements as an emerging market in center construction, equipment localization, and the treatment of characteristic local tumor types. Moving forward, it is essential to continue promoting technological integration and innovation, strengthen high-quality clinical research, and develop a more accessible, intelligent, and personalized proton therapy system to achieve broader clinical application and patient benefit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.